SiftrBio Analysis: $1M Raised
What is SiftrBio?
SiftrBio focuses on developing high efficacy, low side-effect antibody-drug conjugates (ADCs) for difficult-to-treat cancers. The company utilizes human patient tumor tissue to design linkers, moving beyond outdated technologies. Their mission is to improve ADC performance and expand treatment options for cancer patients.
Funding Status
Seed
Product Features & Capabilities
- SIFTR platform for ADC linker development
- High throughput linker design
- Human tissue-based linker optimization
Use Cases
Develop new ADCs for hard-to-treat cancers; Improve efficacy of existing ADCs; Reduce side effects in cancer treatments; Utilize human tumor tissue for linker design; Drive high throughput development of ADC linkers
Other Considerations
Received £1 million investment for ADC development; Awarded £827K grant from EPSRC for ADC linker research; Backed by Imperial College and Cancer Research Horizons
See something that needs updating? Suggest edits to this profile.